Skip to main content
. 2015 Sep 29;16(10):23382–23389. doi: 10.3390/ijms161023382

Figure 1.

Figure 1

MiR-378 and miR-210 as biomarkers in renal cell carcinoma. Differences in serum levels of miR-378 (A) and miR-210 (B) in RCC patients and healthy controls; dynamics of miR-378 (C) and miR-210 (D) levels in blood serum one week and three months after radical nephrectomy; and positive correlation of miR-378 with disease free survival (E) and ROC analysis of miR-378/miR-210 combination for discrimination of renal cell carcinoma patients and healthy controls (F).